News25/Ratings0
Latest news
25 items- INSIDERSEC Form 4: John R Fletcher was granted 8,676 units of Common Stock4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by Marcus Boehm4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by Joanna Horobin4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by Howard Mcleod4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by Yung-Ping Yeh4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by R. Paul Hansen4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by E. Geoffrey Harris4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by Ralf Brandt4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by D.C. Andrew Lafrence4 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 4 filed by A John Roberts4 - Vyant Bio, Inc. (0001349929) (Issuer)
- SECSEC Form 3 filed by Cancer Genetics, Inc.3 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 3 filed by Marcus Boehm3 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 3 filed by John R Fletcher3 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 3 filed by Joanna Horobin3 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 3 filed by D.C. Andrew Lafrence3 - Vyant Bio, Inc. (0001349929) (Issuer)
- INSIDERSEC Form 3 filed by R. Paul Hansen3 - Vyant Bio, Inc. (0001349929) (Issuer)
- PRCancer Genetics and StemoniX Announce Merger ClosingCancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of t
- SECSEC Form 10-K filed by Cancer Genetics, Inc.10-K - CANCER GENETICS, INC (0001349929) (Filer)
- SECSEC Form 8-K filed by Cancer Genetics, Inc.8-K - CANCER GENETICS, INC (0001349929) (Filer)
- PRCancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniXCombined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Commo
- SECSEC Form 425 filed by Cancer Genetics, Inc.425 - CANCER GENETICS, INC (0001349929) (Subject)
- PRCancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business DevelopmentRUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.
- SECSEC Form 8-K filed by Cancer Genetics, Inc.8-K - CANCER GENETICS, INC (0001349929) (Filer)
- SECSEC Form 425 filed by Cancer Genetics, Inc.425 - CANCER GENETICS, INC (0001349929) (Subject)
- PRCancer Genetics to Present at the Annual 33rd ROTH ConferenceRUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the Annual 33rd ROTH Conference. The event is being held virtually from March 15-17, 2021. Conference Date: March 15-17, 2021 (Monday-Wednesday)1x1 Meetings9:00 am-5:55 pm ET (Monday-Wednesday)Registration: Click Here Mr. Roberts will highlight the Company's recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an investor and would li
CGIX FAQ
5 questionsWhere does CGIX stock trade?
Cancer Genetics, Inc. (CGIX) is listed on NASDAQ.What sector and industry is CGIX in?
Cancer Genetics, Inc. operates in the Health Care sector, Medical Specialities industry.When did Cancer Genetics, Inc. go public?
Cancer Genetics, Inc. (CGIX) completed its IPO in n/a.What companies are similar to CGIX?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CGIX side-by-side with any of them on Quantisnow.How can I track CGIX on Quantisnow?
Quantisnow aggregates Cancer Genetics, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGIX to receive live email and push alerts on every new disclosure.